Actelion Pharmaceuticals US, Inc. Sustainability Profile
Actelion Pharmaceuticals US, Inc., a subsidiary of Johnson & Johnson, is a leading biopharmaceutical company headquartered in the United States. Founded in 1997, Actelion has established itself as a pioneer in the development of innovative treatments for pulmonary arterial hypertension (PAH) and other rare diseases. With a strong presence in North America and Europe, the company focuses on delivering unique therapies that improve patients' quality of life. Actelion's core products, including Tracleer and Opsumit, are distinguished by their targeted mechanisms of action and proven efficacy. The company has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which has further solidified its market position. Renowned for its commitment to research and development, Actelion continues to lead the way in addressing unmet medical needs within the biopharmaceutical industry.
DitchCarbon Score
How does Actelion Pharmaceuticals US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Actelion Pharmaceuticals US, Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Actelion Pharmaceuticals US, Inc. currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Johnson & Johnson, and any climate commitments or emissions data would be inherited from its parent organisation. As part of its corporate family relationship with Johnson & Johnson, Actelion Pharmaceuticals aligns with the sustainability initiatives and climate commitments set forth by its parent company. Johnson & Johnson has established various reduction targets and initiatives, including those under the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on transitioning to 100% renewable energy. While specific reduction targets for Actelion Pharmaceuticals are not detailed, the overarching goals from Johnson & Johnson reflect a commitment to reducing greenhouse gas emissions across all scopes. This includes efforts to enhance energy efficiency and transition to renewable energy sources, which are critical components of their climate strategy. In summary, while Actelion Pharmaceuticals US, Inc. does not report specific emissions data or reduction targets independently, it is integrated into the broader sustainability framework of Johnson & Johnson, which actively pursues significant climate commitments and emissions reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Actelion Pharmaceuticals US, Inc.'s Industry?
How Carbon Intensive is Actelion Pharmaceuticals US, Inc.'s Location?
Actelion Pharmaceuticals US, Inc.'s Scope 3 Categories Breakdown
Actelion Pharmaceuticals US, Inc.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Actelion Pharmaceuticals US, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Actelion Pharmaceuticals US, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
